Consistently, activation of the PI3K-AKT-S6K1 pathway induces immune escape and apoptosis of activated T cells, impairing tumor-specific T cell killing through upregulation of PD-L1 on colorectal [79], lung [80], renal [81], breast, and prostate cancer cells [82]. Here, PIK3CB is linked to neoplasm.